|
Mar 17
|
3 Unstoppable Stocks You Can Buy Now Without Any Hesitation
|
|
Mar 14
|
Drugmakers agree to participate in second round of price negotiations
|
|
Mar 14
|
The Zacks Analyst Blog Highlights Novo Nordisk, Roche, Pfizer, Arvinas and J&J
|
|
Mar 14
|
Zacks Market Edge Highlights: Tesla, NVIDIA, JPMorgan Chase, Exxon Mobil and Novo Nordisk
|
|
Mar 14
|
An Ozempic successor falls short, Eli Lilly's GLP-1 pill, and senators grill RFK: Pharma news roundup
|
|
Mar 13
|
Is A Recession Coming in 2025? Where to Invest Now
|
|
Mar 13
|
NVO Stock Slips 4% as Roche Inks Obesity Drug Deal With Zealand
|
|
Mar 13
|
Pharma Stock Roundup: RHHBY Obesity Drug Rights Buyout, NVO Pipeline Update
|
|
Mar 13
|
Wall Street's Biggest Novo Nordisk Bear Just Flipped--Here's Why He Says It's Time to Buy
|
|
Mar 13
|
UiPath plunges on weak outlook, Novo Nordisk upgrade: Top Stocks
|
|
Mar 13
|
How to Play VKTX Stock Amid Manufacturing Deal With CordenPharma
|
|
Mar 13
|
Novo Nordisk Skeptic Finally Upgrades Stock After Drop From Peak
|
|
Mar 12
|
Roche Inks 'The Largest Obesity Deal To Date' With Zealand Pharma At $5.3 Billion
|
|
Mar 12
|
Compounded Wegovy and Zepbound may disappear under new FDA rules
|
|
Mar 12
|
Roche, Zealand sign deal: What it means for weight loss drug space
|
|
Mar 12
|
Novo Nordisk Is Falling. Competition Is a Killer.
|
|
Mar 12
|
Novo Nordisk, Starbucks shares slumping: Trending Tickers
|
|
Mar 12
|
iRobot, Target, Novo Nordisk vs. Roche: Market Minute
|
|
Feb 24
|
Wall Street Thinks This Weight Loss Drug Stock Could More Than 3X Over the Next 12 Months -- and It's Not Eli Lilly or Novo Nordisk
|
|
Feb 23
|
Prediction: These Could Be the Best-Performing Value Stocks Through 2030
|